Your AI-Trained Oncology Knowledge Connection!
Cancer Network and the journal ONCOLOGY present exclusive coverage from the annual meeting of the American Society of Clinical Oncology (ASCO). Visit one of our topic-specific ASCO pages or follow the stories below to catch some of the most important information to come out of this year's event.
Cancer Network and the journal ONCOLOGY present exclusive lung cancer coverage from the annual meeting of the American Society of Clinical Oncology (ASCO). Check out the stories below for write-ups of the most important information to come out of this year's event.
A mouse model of bone metastasis can be used to follow real-time response to therapeutics in preclinical development, such as cabozantinib, according to results presented in the poster session of the 2013 AACR annual meeting.
Cancer Network and the journal ONCOLOGY present exclusive prostate cancer coverage from the annual meeting of the American Society of Clinical Oncology (ASCO). Check out the stories below for write-ups of the most important information to come out of this year's event.
The use of zoledronic acid (Zometa) had no effect on the prevention of bone metastases in patients with high-risk prostate cancer, according to the first results of the Zometa European Study, or ZEUS, presented at the European Association of Urology 28th Annual Congress in Milan, Italy.
Hypofractionated external beam WBI seems like a great option until the APBI data mature from NSABP 39/RTOG 0413. In the meantime, we will have to see whether the ACA’s mission to bend the cost curve in the face of added demand for cancer care will succeed and how our treatment decisions will be affected by this new healthcare model.
APBI is a technique that offers women with early-stage breast cancer a choice. The preponderance of evidence supports the efficacy and safety of this technique, and it should continue to be offered to appropriately selected patients on and off protocol.
Just as high-quality research has focused on limiting the physical toxicity resulting from successful treatment, future research should focus on mitigating the negative effects of financial toxicity without affecting disease-related outcomes.
Accelerated partial-breast irradiation is a shorter, alternative radiation technique for select patients with favorable early-stage breast cancer. We review here the different modalities of delivery and discuss the possible benefits and harms associated with these treatments.
This interview covers symptom management and quality-of-life outcomes in cancer clinical trials, which are being incorporated more readily as secondary and sometimes primary trial endpoints.
Washington, DC-“Triple-negative breast tumors are composed of mosaic cancer cells with distinct genetic aberrations,” said Jorge S. Reis-Filho, MD, PhD, a surgical pathologist at the Memorial Sloan-Kettering Cancer Center in New York, who combines traditional pathology, gene expression profiling, and genomics techniques to understand rare breast tumor types, including triple-negative diseases.
Recently, the US government released new “Sunshine” standards requiring more rigorous disclosure of potential financial conflicts of interest in medicine. Such new standards are driven by revelations of misdeeds on the part of pharmaceutical and device manufacturers.
This interview covers symptom management and quality-of-life outcomes in cancer clinical trials, which are being incorporated more readily as secondary and sometimes primary trial endpoints.
Cancer Network brings exclusive coverage of the AACR Annual Meeting, held April 6-10, 2013 at the Walter E. Washington Convention Center in Washington, D.C. This meeting brings together the best and latest findings in all major areas of cancer research. Through plenary sessions, symposia, forums, educational sessions, methods workshops, poster presentations, conversations with experts and networking, attendees walk away with a wealth of new information, more connections and renewed energy, inspiration and focus in their work. Check below for the most important news to come out of this year's event.
When you start seeing a patient for the first time who has been treated elsewhere and the previous oncologist has not followed standard protocol, how do you present this new way of doing things without alienating the patient or sounding critical of the previous doctor?
THE STRENGTH TO HEAL and stand by those who stand up for me. Learn the latest treatments and play an important role in the care of Soldiers and their families. As a physician on the U.S. Army Reserve health care team, you’ll continue to practice in your community and serve when needed. You’ll work with the most advanced technology and distinguish yourself while working with dedicated professionals. You’ll make a difference.To learn more about the U.S. Army health care team, call 866-213-2077 or visit healthcare.goarmy.com/info/s076
My practice has been concerned that we physicians were not maximizing our “coding potential”; that is, we were not receiving as much remuneration for each cancer patient visit as Medicare permits under its guidelines. Therefore, the practice hired a company that specializes in teaching physicians how to get more. This company is part of a newly minted industry that does nothing else.
Job Description This is a new position, created as the result of the organization’s strategy to become the regional market leader in cancer services in central Pennsylvania. The Medical Director will be responsible for directing physician clinical services as well as developing services and recruiting clinical professionals. This position will also maintain a clinical practice to complement their leadership duties.
We are recruiting board-certified oncologists for full and part time positions. Responsibilities include leading teams of health professionals, peer-to-peer discussions with physicians, collaborating with clinical content specialists; and opportunity for health services research. This position is for the individual seeking a change in career direction that is both dynamic and challenging.
This review covers symptoms and complications in patients with late-stage pancreatic cancer, including venous thromboembolism, anorexia-cachexia, pain, and depression.
If MGTs could predict which patients were most prone to late recurrence and thus might benefit from extended adjuvant endocrine therapy, it would be a huge advancement in the care and survivorship of our patients. More studies of MGTs are required to clarify their role in evaluating prognosis and predicting response to therapy in breast cancer.
Cancer Network brings exclusive coverage of content and expert perspectives from the 38th annual Oncology Nursing Society Congress, held April 25–28, 2013 at the Walter E. Washington Convention Center in Washington, DC. Through educational sessions and symposia, podium and poster presentations, workshops, and special interest group (SIG) meetings, ONS Congress provides myriad opportunities to learn about innovations in cancer treatment and supportive care; ways to integrate and promote evidence-based practice to improve patient outcomes and quality of life; strategies for nursing self-care; and approaches to support professional growth.
One way of framing the ethical question in this case might be: “What are my ethical obligations to provide an anticancer therapy when I think it is unlikely to benefit the patient?” The broader clinical questions involved in this case are fundamentally the same in most patients.
Most Americans are aware that technical experts from Consumer Reports magazine consistently rank televisions and automobiles manufactured by Japanese companies higher than their US counterparts, but I believe that neither Consumer Reports nor US physicians understand how much better lung cancer treatment results are in Japan.
In this interview we discuss the dissemination of research results, clinical trials, and other oncology news using social media, as well as what type of media oncologists use, and how useful and relevant this type of information is for most oncologists.
Along with chemotherapy and surgery, radiation therapy remains one of the three main treatments for cancer. A new article in Science Translational Medicine reviews the recent advances and current challenges in radiation oncology today.
Cancer Network presents exclusive coverage of the 30th Annual Miami Breast Cancer Conference. We speak with nationally recognized breast cancer specialists and bring you their insights into the optimal multidisciplinary management of patients with breast cancer and the application of innovative approaches to practice. As always, we encourage feedback and suggestions on how we can better serve your clinical cancer information needs. Please check your inbox for reports from the 30th Annual Miami Breast Cancer Conference, and watch here for our editorial staff’s coverage during the meeting.
Results from a retrospective analysis indicate that the use of the antiangiogenic, VEGF inhibitor sorafenib for the treatment of advanced renal cell carcinoma was well tolerated in patients aged 65 years or older.
To place responsibility for rationing chemotherapeutics on the oncologist not only increases his or her emotional burden, but it also strains the doctor-patient relationship. We should not allow oncologists to become bedside healthcare rationers simply because no one else wants to do the job.
